Oct 09, 2018
Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress
Oct 03, 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Aug 15, 2018
Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
Jul 09, 2018
Trovagene Presents Outlook for Second Half of 2018
Jun 27, 2018
Kangpu Biopharmaceuticals Launched Phase I Study of Novel Cancer Therapy Candidate KPG-121 in Patients with Metastatic Castration-Resistant Prostate Cancer in Collaboration with Accelovance, Inc.
May 16, 2018
Janssen to Present New Data in Urothelial, Hematologic and Prostate Cancers at ASCO 2018, Including Best of ASCO Selections
Feb 26, 2018
Trovagene Announces Fourth Quarter and Full-Year 2017 Results
Feb 15, 2018
Health Canada Approves New Indication for ZYTIGA®* (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer
Feb 09, 2018
Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium
Feb 08, 2018
ZYTIGA® (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Jan 25, 2018
Janssen to Present 14 Abstracts in Prostate and Urothelial Cancers at ASCO GU 2018, Including New Data on Apalutamide (ARN-509), ZYTIGA® (abiraterone acetate) and Erdafitinib
Jan 24, 2018
Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Jan 18, 2018
Amerigen's petition leads to U.S. Zytiga® patent invalidation
Dec 14, 2017
Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
Nov 09, 2017
Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results
Oct 18, 2017
Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells
Sep 14, 2017
Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA® (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Jun 03, 2017
Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Survival
May 30, 2017
Churchill Pharmaceuticals Expands Commercial Leadership Team